Pliant scientist in a white lab coat and blue gloves using a pipette to fill a small tube

HARNESSING INTEGRINS

Using integrin science to target disease at its source

Integrins, which are naturally occurring cell surface proteins, are the focus of our two-pronged scientific approach:

1. Integrin inhibition
2. Integrin-mediated delivery

1. Integrin inhibition

Integrins are normally expressed at low levels, but in certain diseases they are upregulated. This upregulation can cause issues such as the continuous activation of TGF-β. Our lead product candidate, PLN-101095, is an integrin inhibitor that targets the TGF-β pathway and is currently being studied in the FORTIFY clinical trial for the treatment of solid tumors.

Diagram of the integrin receptor family

Developing product candidates that inhibit integrins and
related pathways

With a deep understanding of integrin biology, as well as medicinal chemistry and translational medicine expertise, we have developed a set of proprietary tools to probe the molecular drivers of disease to identify new targets and discover candidates that inhibit dysregulated integrins and related pathways. By utilizing our proprietary library of over 15,000 integrin binding molecules, a comprehensive screening assay system (binding, integrin confirmation, ligand-induced internalization) and an industry-leading live human tissue program, we are creating a deep well of potential drug candidates.

Pliant scientist in black gloves holding a sample tube over a rack at a lab bench

Our Publications

Our team has unmatched expertise in integrin biology, and we value sharing our knowledge. We regularly publish and present our research in a variety of forums to advance the discovery of novel targeted therapies.

Read all publications